These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Antiangiogenic approaches to age-related macular degeneration in the future. Do DV Ophthalmology; 2009 Oct; 116(10 Suppl):S24-6. PubMed ID: 19800536 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Li H; Lei N; Zhang M; Li Y; Xiao H; Hao X Exp Eye Res; 2012 Apr; 97(1):154-9. PubMed ID: 21933673 [TBL] [Abstract][Full Text] [Related]
26. A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials. Liu M; Regillo CD Curr Opin Ophthalmol; 2004 Jun; 15(3):221-6. PubMed ID: 15118509 [TBL] [Abstract][Full Text] [Related]
27. Emerging biological therapies for the treatment of age-related macular degeneration. Asahi MG; Avaylon J; Wallsh J; Gallemore RP Expert Opin Emerg Drugs; 2021 Jun; 26(2):193-207. PubMed ID: 34030572 [TBL] [Abstract][Full Text] [Related]
28. Age-related macular degeneration and the other double helix. The Cogan Lecture. Ambati J Invest Ophthalmol Vis Sci; 2011 Apr; 52(5):2165-9. PubMed ID: 21471430 [TBL] [Abstract][Full Text] [Related]
29. CCR3: Shedding new light on a dark problem? Mason AB; Hoh J J Mol Cell Biol; 2009 Oct; 1(1):17-9. PubMed ID: 19684049 [TBL] [Abstract][Full Text] [Related]
30. Nanodiagnostics and Nanotherapeutics for age-related macular degeneration. Sarkar A; Dyawanapelly S J Control Release; 2021 Jan; 329():1262-1282. PubMed ID: 33129920 [TBL] [Abstract][Full Text] [Related]
32. [Adapted and standardised patient management in the treatment of neovascular AMD in the outpatient setting of a university eye hospital]. Framme C; Wolf-Schnurrbusch UE; Lobsiger H; Bayer S; Wolf S Klin Monbl Augenheilkd; 2012 Aug; 229(8):812-21. PubMed ID: 22615063 [TBL] [Abstract][Full Text] [Related]
33. A novel quadraport needle with improved intravitreal drug dispersion. Asami T; Wong SC; Mitchell PC; Tokunaga CC; Chen YH; Dang L; Giblin FJ; Trese MT Retina; 2012 Jun; 32(6):1222-5. PubMed ID: 22596098 [No Abstract] [Full Text] [Related]
35. Steerable intravitreal inserts for drug delivery: in vitro and ex vivo mobility experiments. Bergeles C; Kummer MP; Kratochvil BE; Framme C; Nelson BJ Med Image Comput Comput Assist Interv; 2011; 14(Pt 1):33-40. PubMed ID: 22003597 [TBL] [Abstract][Full Text] [Related]
36. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat(®), for age-related macular degeneration. Binley K; Widdowson PS; Kelleher M; de Belin J; Loader J; Ferrige G; Carlucci M; Esapa M; Chipchase D; Angell-Manning D; Ellis S; Mitrophanous K; Miskin J; Bantseev V; Nork TM; Miller P; Naylor S Hum Gene Ther; 2012 Sep; 23(9):980-91. PubMed ID: 22716662 [TBL] [Abstract][Full Text] [Related]
37. Intravitreal injections: a most recent evidence for best practice. Grzybowski A; Ascaso FJ Clin Exp Ophthalmol; 2013 Nov; 41(8):816-7. PubMed ID: 23844649 [No Abstract] [Full Text] [Related]
38. Intravitreal injections: a most recent evidence for best practice--response. Fagan XJ; Al-Qureshi S Clin Exp Ophthalmol; 2013 Nov; 41(8):817-8. PubMed ID: 23844624 [No Abstract] [Full Text] [Related]
39. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Avery RL; Bakri SJ; Blumenkranz MS; Brucker AJ; Cunningham ET; DʼAmico DJ; Dugel PU; Flynn HW; Freund KB; Haller JA; Jumper JM; Liebmann JM; McCannel CA; Mieler WF; Ta CN; Williams GA Retina; 2014 Dec; 34 Suppl 12():S1-S18. PubMed ID: 25489719 [TBL] [Abstract][Full Text] [Related]
40. A Prediction Model for the Intraocular Pharmacokinetics of Intravitreally Injected Drugs Based on Molecular Physicochemical Properties. Kim HM; Park KH; Chung JY; Woo SJ Ophthalmic Res; 2020; 63(1):41-49. PubMed ID: 31112980 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]